Ligand Pharmaceuticals (LGND) vs Travere Therapeutics (TVTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Travere Therapeutics (TVTX) has outperformed Ligand Pharmaceuticals (LGND) over the past year, gaining 99.9% versus a gain of 65.5%. Over five years, LGND leads with a +271.4% price change compared with +112.8% for TVTX. Ligand Pharmaceuticals is the larger company by market cap ($6.02 billion vs $4.91 billion), about 1.2 times the size, while Travere Therapeutics is growing revenue faster (+110.5% vs +60.4%).
On valuation, Travere Therapeutics trades at a lower forward P/E (9.2x vs 25.3x for Ligand Pharmaceuticals). Ligand Pharmaceuticals converts more of its revenue into profit, with a net margin of 46.4% versus -5.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LGND | TVTX |
|---|---|---|
| Share price | $301.81 | $52.13 |
| Market cap | $6.02B | $4.91B |
| 1-day change | +2.31% | +0.16% |
| YTD return | +59.63% | +36.42% |
| 1-year return | +65.54% | +99.94% |
| 5-year return | +271.41% | +112.76% |
| P/E ratio (TTM) | 31.80 | — |
| Forward P/E | 25.26 | 9.24 |
| EPS (TTM) | $9.49 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $268.09M | $490.73M |
| Revenue growth (YoY) | +60.40% | +110.45% |
| Net income (latest FY) | $124.45M | $-25.55M |
| Gross margin | — | 97.89% |
| Operating margin | 15.29% | -12.80% |
| Net margin | 46.42% | -5.21% |
| 52-week high | $326.63 | $68.73 |
| 52-week low | $175.89 | $22.59 |
| Distance from 52-week high | -7.60% | -24.16% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +14.06% | +44.29% |
| Average volume | 259.13K | 1.59M |
| Shares outstanding | 19.94M | 94.26M |
| Employees | 47 | 497 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TVTX has outperformed LGND by 34.4 percentage points over the past year.
- Ligand Pharmaceuticals is more profitable, keeping 46.4 cents of every revenue dollar as net income versus -5.2 cents for Travere Therapeutics.
- Travere Therapeutics grew revenue faster in its latest fiscal year (+110.45% vs +60.40%).
About Ligand Pharmaceuticals
LGND stock →Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 47 employees
About Travere Therapeutics
TVTX stock →Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Health Care · Biotechnology: Pharmaceutical Preparations · 497 employees
LGND vs TVTX FAQ
Which is bigger, Ligand Pharmaceuticals or Travere Therapeutics?
Ligand Pharmaceuticals (LGND) is larger, with a market capitalization of $6.02B compared with $4.91B for Travere Therapeutics (TVTX).
Which stock has performed better over the past year, LGND or TVTX?
TVTX returned +99.94% over the past 12 months, compared with +65.54% for LGND (price return, excluding dividends). Past performance does not predict future results.
Are Ligand Pharmaceuticals and Travere Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.